Tech Company Financing Transactions

TetraLogic Pharmaceuticals Funding Round

TetraLogic Pharmaceuticals secured a $32 million Series C funding round on 8/11/2010. Investors included Clarus, Amgen Ventures and Hatteras Venture Partners.

Transaction Overview

Company Name
TetraLogic Pharmaceuticals
Announced On
8/11/2010
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series C
Investors

Clarus (Lead Investor) (Michael Steinmetz)

Amgen Ventures

Hatteras Venture Partners (Douglas Reed)

HealthCare Ventures (Harold Werner)

Latterell Venture Partners (Larry Lasky)

Novitas Capital (Paul Schmitt)

Quaker Partners (Brenda Gavin)

The Vertical Group

Proceeds Purpose
Proceeds from the financing will be used to advance clinical development of TL32711, TetraLogic's lead drug candidate for the treatment of cancer. TL32711 is a SMAC mimetic that neutralizes the activity of inhibitor of apoptosis proteins (IAPs) that block tumor cell death. TL32711 is being evaluated in a Phase 1 study as a single agent in patients with solid tumors and lymphoma refractory to standard therapies.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
343 Phoenixville Pike
Malvern, PA 19355
USA
Phone
(610) 889-9900
Website
www.tetralogicpharma.com
Email Address
[email protected]
Overview
TetraLogic Pharmaceuticals (NASDAQ: TLOG) discovers and develops novel, targeted drugs to treat cancer.
Profile
TetraLogic Pharmaceuticals LinkedIn Company Profile
Social Media
TetraLogic Pharmaceuticals Company Twitter Account
Company News
TetraLogic Pharmaceuticals News
Facebook
TetraLogic Pharmaceuticals on Facebook
YouTube
TetraLogic Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Kevin Buchi
  Kevin Buchi LinkedIn Profile  Kevin Buchi Twitter Account  Kevin Buchi News  Kevin Buchi on Facebook
Chief Financial Officer
Patrick Hutchison
  Patrick Hutchison LinkedIn Profile  Patrick Hutchison Twitter Account  Patrick Hutchison News  Patrick Hutchison on Facebook
Chief Medical Officer
Jeffrey Skolnik
  Jeffrey Skolnik LinkedIn Profile  Jeffrey Skolnik Twitter Account  Jeffrey Skolnik News  Jeffrey Skolnik on Facebook
Chief Scientific Officer
Stephen Condon
  Stephen Condon LinkedIn Profile  Stephen Condon Twitter Account  Stephen Condon News  Stephen Condon on Facebook
VP - General Counsel
Richard Sherman
  Richard Sherman LinkedIn Profile  Richard Sherman Twitter Account  Richard Sherman News  Richard Sherman on Facebook
VP - Operations
Tony Meehan
  Tony Meehan LinkedIn Profile  Tony Meehan Twitter Account  Tony Meehan News  Tony Meehan on Facebook
VP - R & D
Glenn Begley
  Glenn Begley LinkedIn Profile  Glenn Begley Twitter Account  Glenn Begley News  Glenn Begley on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/11/2010: Dicerna Pharmaceuticals venture capital transaction
Next: 8/11/2010: TwinStrata venture capital transaction

 

Share this article

 

News on VC Transactions

We report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.